Document is current

Article History

Accepted: 1 October 2023

First Online: 24 October 2023

Declarations

:

: The only funding for this article was provided by Bristol Myers Squibb for medical writing support.

: Paul Beninger has had consulting relationships with Oncopeptides AB (in 2021) and with Moderna Therapeutics (in 2022). He is also a co-Editor-in-Chief for Clinical Therapeutics. John Marcinak and Ritu Raheja are full-time employees of AbbVie and hold stock with AbbVie. Loreta Marquez is a full-time employee of Janssen R&D and holds stock with Johnson and Johnson. Curtis Chang is a full-time employee of Takeda. Liliam Pineda Salgado and Alvin Estilo are full-time employees of Otsuka Pharmaceutical Development and Commercialization, Inc. Jason Jiang was a full-time employee of Daiichi Sankyo, Inc. until August 25, 2022. May Chan-Liston was a full-time employee of Bristol Myers Squibb and held company stock until September 28, 2022.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: LM, RR, MC-L, JM, AE, LPS, Jason Jiang, and CC contributed to the conception of this review, the literature search and data analysis, and all drafts. PB critically reviewed and contributed to the pre-final draft. All authors read and approved the final manuscript, for which they take public responsibility and have full confidence in its accuracy and integrity.